The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2021 | Novel agents for consolidation after auto-SCT in myeloma
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, gives an overview of novel agents for consolidation after autologous stem cell transplantation (auto-SCT) for patients with myeloma. Dr Gagelmann highlights data from a study investigating lenalidomide, dexamethasone and bortezomib, and data from a study investigating quadruplet therapy with daratumumab and an immunomodulatory drug, commenting on the need for longer follow-up. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
